In recent years, the scientific community has made significant strides in the field of organoid research, a domain that sits at the confluence of stem cell science, developmental biology, and biomedical engineering. Organoids, essentially miniaturised and simplified versions of organs produced in vitro, offer a promising avenue for understanding human development, disease modelling, and potentially paving the way for personalised medicine. Yet, despite their potential, one of the enduring challenges has been manipulating these organoids to mimic the complex spatial and temporal patterns of gene expression observed in natural organ development.

Radiation-induced lung injury (RILI) is a severe and life-threatening condition that arises from exposure to high doses of ionizing radiation. Such exposures can occur during radiological disasters, nuclear incidents, or as an unintended side effect of radiation therapy for cancer. Understanding the intricacies of RILI is essential to improve the outcomes for cancer patients undergoing radiation therapy.

Biopharmaceuticals, encompassing proteins and peptides, have significantly impacted the treatment of various diseases like diabetes, heart disorders, and cancer. However, a major drawback is that these drugs mostly need to be injected due to their large size and instability. Over the years, attempts to create oral forms of some of these drugs have faced challenges, particularly in getting them absorbed efficiently in the body.

The successful integration of electronic devices with delicate biotissues relies on seamless interfacing. A recent article titled "Bioadhesive polymer semiconductors and transistors for intimate biointerfaces" addresses this challenge by introducing a novel bioadhesive polymer semiconductor. This promises to improve the way we use bioelectronic devices for real-time biological signal measurement and health monitoring.

As the field of spatial omics gains traction, the need for highly multiplexed images is on the rise. However, creating such images poses significant challenges, including cost, technical expertise, and limitations in available technology. One solution is the registration of collections of whole slide images (WSI) to generate spatially aligned datasets. This opens doors for advanced spatial analyses and holds the potential to transform our understanding of cellular interactions and tissue structure within the tumour microenvironment.

Cancer, a complex and multifaceted disease, is often initiated by genetic mutations that act as driving forces for tumour growth. These genetic changes, known as oncogenic driver events, are central to our understanding of cancer development. However, the intricate mechanisms through which these drivers exert their influence on the cellular machinery remain a puzzle yet to be fully solved. In this study, researchers have employed a comprehensive approach, merging genomics and proteomics, to shed light on the connections between oncogenic drivers and the functional states of cancer cells.

In a clinical study, scientists have assessed the power of artificial intelligence (AI) to transform the landscape of mammography screening. The Mammography Screening with Artificial Intelligence trial (MASAI) introduces an innovative AI-supported screen-reading protocol, revolutionising how radiologists interpret mammograms. Unlike previous retrospective studies, MASAI is the first-of-its-kind randomised trial to investigate the clinical safety and effectiveness of AI integration in mammography screening.

In a remarkable fusion of biology and technology, scientists have achieved a significant breakthrough by engineering bacteria to act as precision DNA detectives. The latest research by Cooper et al. introduces a concept where bacteria, specifically Acinetobacter baylyi, are transformed into dynamic biosensors capable of detecting specific mutations in human DNA. What makes this achievement truly remarkable is that these bacteria, known for their nonpathogenic nature and natural competence for DNA uptake, have been harnessed to spot cancer-associated mutations, offering a potential pathway for early cancer detection and targeted treatment.

Cancer, with its intricate and diverse processes across various scales and fields, demands a multidisciplinary effort. To tackle this complexity, a consortium of experts in cancer and philosophy has proposed an innovative approach that melds scientific experimentation with philosophical inquiry. By intertwining applied sciences, including clinical and experimental research, with conceptual and theoretical insights, this review aims to foster a more integrated understanding of cancer. Through a comprehensive exploration of six key themes, such as mutations, tumour microenvironment, and immune system dynamics, the researchers exemplify how philosophical methods can augment scientific comprehension.

This study introduces a new method that combines CRISPR-Cas gene-editing technology and molecular barcoding for improved cancer detection. By stabilising DNA to act as molecular barcodes, researchers triggered diagnostic signals in response to disease-related changes. CRISPR nucleases were then employed to detect these signals, offering a specific readout for diagnostics. This approach could lead to non-invasive and rapid cancer detection, showcasing the potential of converging scientific fields for significant healthcare advancements.

Collaborating across London and Milan, a groundbreaking study delves into immune selection's role in tumour development and checkpoint inhibitor effectiveness. By analysing immune dN/dS – a mutation ratio within immune-interacting regions – two tumour categories emerged: immune-edited (shedding antigenic mutations) and immune-escaped (masking antigenicity). CD8 T cell infiltration linked to immune-edited tumours, while immune-escaped ones responded better to immunotherapy. Nivolumab treatment targeted neoantigens in nonimmune-edited patients. This study emphasizes understanding tumour evolution for improved personalised medicine, suggesting new approaches for refining cancer treatment strategies.

Imperial College London researchers have developed graphene biosensors that could revolutionize early disease detection. These biosensors utilize graphene field effect transistors (GFETs) to rapidly and accurately identify pancreatic cancer, offering a portable and versatile diagnostic tool. By detecting cancer-specific exosomes, the GFET biosensor platform shows promising potential for enhancing healthcare and improving patient outcomes.

Researchers from MIT's Koch Institute for Integrative Cancer Research have unveiled a pioneering approach in cancer immunotherapy. By combining CD4+ T cells, STING signaling, and immune checkpoint blockade (ICB), the study offers a novel strategy to eradicate tumors. This innovative synergy not only highlights the potential of CD4+ T cells but also addresses STING deficiency, paving the way for more effective and personalized cancer treatments.

A pioneering convergence of genetics, engineering, and electronics has created a miniaturised biosensor. Nitric oxide and hydrogen sulfide, elusive inflammation signals, are detected by engineered probiotic bacteria linked to electronic circuits. This innovation offers real-time insight into gut health, promising early disease detection and personalised care.

Nikolaus Rajewsky, Geneviève Almouzni, Stanislaw A. Gorski, Stein Aerts, Ido Amit, Michela G. Bertero, Christoph Bock, Annelien L. Bredenoord, Giacomo Cavalli, Susanna Chiocca, Hans Clevers, Bart De Strooper, Angelika Eggert, Jan Ellenberg, Xosé M. Fernández, Marek Figlerowicz, Susan M. Gasser, Norbert Hubner, Jørgen Kjems, Jürgen A. Knoblich, Grietje Krabbe, Peter Lichter, Sten Linnarsson, Jean-Christophe Marine, LifeTime Community Working Groups - Nature 2020

Kyle Swanson, Eric Wu, Angela Zhang, Ash A Alizadeh, James Zou - Cell, 2023

A team of researchers led by Regina Barzilay has developed an approach that marries artificial intelligence with personalisation to optimise the balance between early detection and the avoidance of unnecessary screenings in breast cancer. This innovative method, known as Tempo, has shown promising results in improving breast cancer screening protocols by tailoring them to individual risk levels assessed through AI models.

Hadi T Nia, Lance L Munn, Rakesh K Jain. Science. 2020 Oct 30;370(6516):eaaz0868.

Dario Bressan, Giorgia Battistoni, Gregory J Hannon. Science. 2023 Aug 4;381(6657):eabq4964.

João Conde, Robert Langer, José Rueff. Nat Nanotechnol. 2023 Jun;18(6):537-540.

Genevieve L Stein-O'Brien, Dung T Le, Elizabeth M Jaffee, Elana J Fertig, Neeha Zaidi. Cancer Discov. 2023 May 4;13(5):1053-1057.

Fabrizio Mattei, Mohit Kumar Jolly. iScience. 2023 Apr 18;26(5):106507.

Claire Dilliway, Oliver Dyer, Elena Mandrou, Daniel Mitchell, Govind Menon, Hugh Sparks, Valentin Kapitany, Alex Payne-Dwyer. iScience. 2022 Nov 25;25(12):105615.

Stephen W Smye, Robert A Gatenby. iScience. 2022 Aug 27;25(9):105015.

National Academies of Sciences, Engineering, and Medicine; Division on Earth and Life Studies; Division on Engineering and Physical Sciences; Board on Life Sciences; Board on Physics and Astronomy; Committee on Biological Physics/Physics of Living Systems: A Decadal Survey

Sierra A Walker, Anthony Pham, Sara Nizzero, Mingee Kim, Bob Riter, Julie Bletz, Sheila Judge, Benette Phillips, Dorottya Noble, Diana Murray, Erin Wetzel, Susan Samson, Mariah McMahon, Carl Flink, Jennifer Couch, Claire Tomlin, Kristin Swanson, Alexander R A Anderson, David Odde, Haifa Shen, Shannon Hughes, Nastaran Zahir, Heiko Enderling, Joy Wolfram. Trends Cancer. 2021 Jan;7(1):3-9.

Karolina Urbanska, Sylvie Huet, Serge Guimond. PLoS One. 2019 Sep 4;14(9):e0221907

Susan Samson, Jason J Northey, Vicki Plaks, Carole Baas, Ivory Dean, Mark A LaBarge, Andrei Goga, Laura J Van't Veer, Valerie M Weaver Trends Cancer. 2018 Apr;4(4):260-264.

Michael J Mitchell, Rakesh K Jain, Robert Langer Nat Rev Cancer. 2017 Nov;17(11):659-675